SEARCH

SEARCH BY CITATION

References

  • CALIGNANO, A., LA RANA, G., MAKRIYANNIS, A., LIN, S.Y., BELTRAMO, M. & PIOMELLI, D. (1997). Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur. J. Pharmacol., 340, R7R8.
  • CAPASSO, R., IZZO, A.A., FEZZA, F., PINTO, A., CAPASSO, F., MASCOLO, N. & DI MARZO, V. (2001). Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br. J. Pharmacol., 134, 945950.
  • CAPASSO, R., MATIAS, I., LUTZ, B., BORRELLI, F., CAPASSO, F., MORSICANO, G., MASCOLO, N., PETROSINO, S., MONORY, K., VALENTI, M., DI MARZO, V. & IZZO, A.A. (2005). Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology, 129, 941951.
  • CARAI, M.A.M., COLOMBO, G. & GESSA, G.L. (2004). Rapid tolerance to the intestinal prokinetic effect of cannabinoid CB1 receptor antagonist, SR 141716 (rimonabant). Eur. J. Pharmacol., 494, 221224.
  • CHESER, G.B., DAHL, C.J., EVERINGHAM, M., JAKSON, D.M., MARCHANT-WILLIAMS, H. & STARMER, G.A. (1973). The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice. Br. J. Pharmacol., 49, 588594.
  • COLOMBO, G., AGABIO, R., LOBINA, C., REALI, R. & GESSA, G.L. (1998). Cannabinoid modulation of intestinal propulsion in mice. Eur. J. Pharmacol., 344, 6769.
  • CORCHERO, J., MANZANARES, J. & FUENTES, J.A. (2004). Cannabinoid/opioid crosstalk in the central nervous system. Crit Rev Neurobiol, 16, 159172.
  • COTA, D., TSCHÖP, M.H., HORVAT, L. & LEVINE, A.S. (2006). Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res. Rev., 51, 85107.
  • COUTTS, A.A. & PERTWEE, R. (1997). Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br. J. Pharmacol., 121, 15571566.
  • CROCI, T. & BIANCHETTI, A. (1992). Stimulation of faecal excretion in rats by alpha 2-adrenergic antagonists. J. Pharm. Pharmacol., 44, 358360.
  • CROCI, T., MANARA, L., AUREGGI, G., GUAGNINI, F., RINALDI-CARMONA, M., MAFFRAND, J.P., LEFUR, G., MUKENGE, S. & FERLA, G. (1998). In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br. J. Pharmacol., 125, 13931395.
  • DESPRÉS, J.P., GOLAY, A., SJOSTROM, L. & Rimonabant in Obesity-Lipids Study Group (2005). Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med., 353, 21212134.
  • DI MARZO, V., GOPARAJU, S.K., WANG, L., LIU, J., BATKAI, S., JARAI, Z., FEZZA, F., MIURA, G.I., PALMITER, R.D., SUGIURA, T. & KUNOS, G. (2001). Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 410, 822825.
  • DUNCAN, M., DAVISON, J.S. & SHARKEY, A. (2005). Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment. Pharmacol. Ther., 22, 667683.
  • HEINEMANN, A., SHAHBAZIAN, A. & HOLZER, P. (1999). Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology, 38, 12891297.
  • HOWLETT, A.C., BARTH, F., BONNER, T.I., CABRAL, G., CASELLAS, P., DEVANE, W.A., FELDER, C.C., HERKENHAM, M., MACKIE, K., MARTIN, B.R., MECHOULAM, R. & PERTWEE, R.G. (2002). International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161202.
  • HUNGUND, B.L., SZAKALL, I., ADAM, A., BASAVARAJAPPA, B.S. & VADASZ, C. (2003). Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J. Neurochem., 84, 698704.
  • IZZO, A.A., CAPASSO, R., PINTO, L., DI CARLO, G., MASCOLO, N. & CAPASSO, F. (2001a). Effect of vanilloid drugs on gastrointestinal transit in mice. Br. J. Pharmacol., 132, 14111416.
  • IZZO, A.A., FEZZA, F., CAPASSO, R., BISOGNO, T., PINTO, L., IUVONE, T., ESPOSITO, G., MASCOLO, N., DI MARZO, V. & CAPASSO, F. (2001b). Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol., 134, 563570.
  • IZZO, A.A., MASCOLO, N., BORRELLI, F. & CAPASSO, F. (1999a). Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 359, 6570.
  • IZZO, A.A., MASCOLO, N. & CAPASSO, F. (2001c). The gastrointestinal pharmacology of cannabinoids. Curr. Opin. Pharmacol., 1, 597603.
  • IZZO, A.A., MASCOLO, N., PINTO, L., CAPASSO, R. & CAPASSO, F. (1999b). The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur. J. Pharmacol., 384, 3742.
  • IZZO, A.A., MASCOLO, N., TONINI, M. & CAPASSO, F. (2000). Modulation of peristalsis by cannabinoid CB(1) ligands in the isolated guinea-pig ileum. Br. J. Pharmacol., 129, 984990.
  • KULKARNI-NARLA, A. & BROWN, D.R. (2001). Opioid, cannabinoid and vanilloid receptor localization on porcine cultured myenteric neurons. Neurosci. Lett., 308, 153156.
  • KURZ, A. & SESSLER, D. (2003). Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs, 63, 649671.
  • LAW, P.Y. & LOH, H.H. (1999). Regulation of opioid receptor activities. J. Pharmacol. Exp. Ther., 289, 607624.
  • NAASSILA, M., PIERREFICHE, O., LEDENT, C. & DAOUST, M. (2004). Decreased alcohol self-administration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice. Neuropharmacology, 46, 243253.
  • NAGAKURA, Y., NAITOH, Y., KAMATO, T., YAMANO, M. & MIYATA, K. (1996). Compounds possessing 5-HT3 receptor antagonistic activity inhibit intestinal propulsion in mice. Eur. J. Pharmacol., 311, 6772.
  • PERTWEE, R.G. (2001). Cannabinoids and the gastrointestinal tract. Gut, 48, 859867.
  • PERTWEE, R.G., FERNANDO, S.R., NASH, J.E. & COUTTS, A.A. (1996). Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br. J. Pharmacol., 118, 21992205.
  • ROSS, R.A., BROCKIE, H.C., FERNANDO, S.R., SAHA, B., RAZDAN, R.K. & PERTWEE, R.G. (1998). Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine. Br. J. Pharmacol., 125, 13451351.
  • SHOOK, J.E. & BURKS, T.F. (1989). Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J. Pharmacol. Exp. Ther., 249, 444449.
  • STEINER, H., BONNER, T.I., ZIMMER, A.M., KITAI, S.T. & ZIMMER, A. (1999). Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A., 96, 57865790.
  • STORR, M., SIBAEV, A., MARSICANO, G., LUTZ, B., SCHUSDZIARRA, V., TIMMERMANS, J.-P. & ALLESCHER, H.D. (2004). Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. Am. J. Physiol. Gastrointest. Liver Physiol., 286, G110G117.
  • VAN GAAL, L.F., RISSANEN, A.M., SCHEEN, A.J., ZIEGLER, O., ROSSNER, S. & RIO-Europe Study Group (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 365, 13891397.
  • WALKER, J.M., HUANG, S.M., STRANGMAN, N.M., TSOU, K. & SAÑUDO-PEÑA, M.C. (1999). Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. U.S.A., 96, 1219812203.
  • ZIMMER, A., ZIMMER, A.M., HOHMANN, A.G., HERKENHAM, M. & BONNER, T.I. (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A., 96, 57805785.